On September 8, 2023, doctors from the Vietnam National Children’s Hospital, in collaboration with the research team of ANABIO R&D Co. Ltd, continued to announce the results of a study on the effectiveness of nasal-spraying containing Bacillus spore probiotics (LiveSpo Navax) in the Scientific Reports – Nature journal, entitled “Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics”.
Scientific Reports, belonging to the Nature system, is a famous medical journal in the world. The second replication of this remarkable study in Scientific Reports – Nature proves its scientific rigor and quality, rather than being mere luck.
LiveSpo Navax is an ear, nose, and throat cleaning solution containing more than 5 billion spore probiotics of Bacillus subtilis and Bacillus clausii, along with physiological saline solution (NaCl 0.9%) in a sufficient 5 mL volume. This product is dedicated to cleaning the ear, nose, and throat; it helps prevent and reduce the risk of ear, nose, and throat infections while also supplementing spore probiotics to protect and recover the nasal mucosa.
This study is a double-blind, randomized, and controlled clinical trial, the first of its kind in the world, demonstrating the safety and effectiveness of nasal-spraying Bacillus liquid-form probiotics (LiveSpo Navax) in the treatment of acute respiratory tract infections (ARTIs) in children infected with the influenza virus. The research results show that LiveSpo Navax, when administered directly into the nasal cavity, rapidly reduces the symptoms of ARTIs, significantly shortening the recovery time by more than 2 days. Furthermore, the combination of LiveSpo Navax and standard therapy enhances treatment effectiveness by 58% in the treatment of all acute respiratory tract infection (ARTI) symptoms due to influenza virus.
Especially, LiveSpo Navax significantly inhibits the multiplication of the influenza virus (by 417-fold), reduces bacterial co-infection concentrations such as S. pneumoniae, H. influenzae (by 1152-fold), and enhances immune regulation, reducing the risk of the ‘cytokine storm’ by effectively reducing pro-inflammatory cytokines like IL-6, IL-8, and TNF-α by 1.1 – 53,9-fold. This was 26-fold (for viral loads), 65-fold (for bacterial co-infection concentrations), 1.1 – 9.5-fold (for cytokine levels), and 1.3-fold (for IgA levels) more effective than the control standard-of-care group. Through two publications on the effects of Bacillus spore probiotics originating from Vietnam, Dr. Nguyen Hoa Anh – Director of ANABIO R&D Co. Ltd., reaffirms that nasal spray is not only effective in capturing and inactivating one type of virus but can also assist in the treatment of respiratory tract infections in general, including emerging viruses such as RSV, influenza, adenovirus, SARS-CoV-2, etc. This is because the mechanism of interaction between Bacillus spores with the nasal mucosal immune system, virus, and bacteria is non-specific. Nasal-spraying containing Bacillus spore probiotics can enhance the protective barrier, compete with viruses and bacteria on the nasal mucosa surface, and boost immune responses. LiveSpo Navax has the advantage of being simple to use, cost-effective, and enhancing the effectiveness of vaccines and drugs in preventing and treating viral infections, as well as reducing the cost and duration of treatment with antibiotics in cases of bacterial co-infection. These factors make nasal-spraying LiveSpo Navax an ideal solution for developing countries that have limited medical resources and face challenges with hospital overload, and reduce dependence on antibiotics. In the near future, we will conduct further clinical trials to evaluate the preventive effects of nasal-spraying Bacillus spores (LiveSpo Navax) on respiratory tract infections in children during the transitional season, especially when there is a high prevalence of viral and bacterial pathogens.